ArticlePharmaceuticals (Basel, Switzerland)2022

Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the 'Real-Life' Setting.

Moran Gadot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.